메뉴 건너뛰기




Volumn 9, Issue , 2015, Pages 1779-1784

One-year outcome of bevacizumab therapy for chronic macular edema in central and branch retinal vein occlusions in real-world clinical practice in the UK

Author keywords

Chronic; Laser; Loading dose; Risk factors; Subretinal fluid

Indexed keywords

BEVACIZUMAB; TRIAMCINOLONE;

EID: 84942768131     PISSN: 11775467     EISSN: 11775483     Source Type: Journal    
DOI: 10.2147/OPTH.S89147     Document Type: Article
Times cited : (16)

References (31)
  • 1
    • 77952890912 scopus 로고    scopus 로고
    • Natural history of central retinal vein occlusion: An evidence-based systematic review
    • McIntosh RL, Rogers SL, Lim L, et al. Natural history of central retinal vein occlusion: an evidence-based systematic review. Ophthalmology. 2010;117(6):1113–1123.e15.
    • (2010) Ophthalmology , vol.117 , Issue.6
    • McIntosh, R.L.1    Rogers, S.L.2    Lim, L.3
  • 2
    • 0029842865 scopus 로고    scopus 로고
    • Prevalence and associations of retinal vein occlusion in Australia. The Blue Mountains Eye Study
    • Mitchell P, Smith W, Chang A. Prevalence and associations of retinal vein occlusion in Australia. The Blue Mountains Eye Study. Arch Oph­thalmol. 1996;114:1243–1247.
    • (1996) Arch Oph­thalmol , vol.114 , pp. 1243-1247
    • Mitchell, P.1    Smith, W.2    Chang, A.3
  • 3
    • 75149172639 scopus 로고    scopus 로고
    • The prevalence of retinal vein occlusion: Pooled data from population studies from the United States, Europe, Asia, and Australia
    • Rogers S, McIntosh RL, Cheung N, et al. The prevalence of retinal vein occlusion: pooled data from population studies from the United States, Europe, Asia, and Australia. Ophthalmology. 2010;117(2):313–319.
    • (2010) Ophthalmology , vol.117 , Issue.2 , pp. 313-319
    • Rogers, S.1    McIntosh, R.L.2    Cheung, N.3
  • 4
    • 84942796059 scopus 로고    scopus 로고
    • The Royal College of Ophthalmology, Accessed July 17, 2015
    • The Royal College of Ophthalmology. Interim guidelines for manage­ment of retinal vein occlusion. Available from: https://www.rcophth.ac.uk/wp-content/uploads/2014/12/2010-SCI-095-RVO-Interim-Guidelines-Dec-2010-FINAL.pdf. Accessed July 17, 2015.
    • Interim Guidelines for manage­ment of Retinal Vein Occlusion
  • 5
    • 77952889477 scopus 로고    scopus 로고
    • CRUISE Investiga­tors. Ranibizumab for macular edema following central retinal vein occlusion: Six-month primary end point results of a phase III study
    • Brown DM, Campochiaro PA, Singh RP, et al; CRUISE Investiga­tors. Ranibizumab for macular edema following central retinal vein occlusion: six-month primary end point results of a phase III study. Ophthalmology. 2010;117(6):1124–1133.
    • (2010) Ophthalmology , vol.117 , Issue.6 , pp. 1124-1133
    • Brown, D.M.1    Campochiaro, P.A.2    Singh, R.P.3
  • 6
    • 84867100215 scopus 로고    scopus 로고
    • BRAVO and CRUISE Study Groups. Improved vision-related function after ranibizumab for macu­lar edema after retinal vein occlusion: Results from the BRAVO and CRUISE trials
    • Varma R, Bressler NM, Suñer I, et al; BRAVO and CRUISE Study Groups. Improved vision-related function after ranibizumab for macu­lar edema after retinal vein occlusion: results from the BRAVO and CRUISE trials. Ophthalmology. 2012;119(10):2108–2118.
    • (2012) Ophthalmology , vol.119 , Issue.10 , pp. 2108-2118
    • Varma, R.1    Bressler, N.M.2    Suñer, I.3
  • 7
    • 84862817252 scopus 로고    scopus 로고
    • Ranibizumab for macular edema due to retinal vein occlusions: Long-term follow-up in the HORIZON trial
    • Heier JS, Campochiaro PA, Yau L, et al. Ranibizumab for macular edema due to retinal vein occlusions: long-term follow-up in the HORIZON trial. Ophthalmology. 2012;119(4):802–809.
    • (2012) Ophthalmology , vol.119 , Issue.4 , pp. 802-809
    • Heier, J.S.1    Campochiaro, P.A.2    Yau, L.3
  • 8
    • 84891631064 scopus 로고    scopus 로고
    • RETAIN Study Group. Long-term outcomes in patients with retinal vein occlusion treated with ranibi­zumab: The RETAIN study
    • Campochiaro PA, Sophie R, Pearlman J, et al; RETAIN Study Group. Long-term outcomes in patients with retinal vein occlusion treated with ranibi­zumab: the RETAIN study. Ophthalmology. 2014;121(1):209–219.
    • (2014) Ophthalmology , vol.121 , Issue.1 , pp. 209-219
    • Campochiaro, P.A.1    Sophie, R.2    Pearlman, J.3
  • 9
    • 84908658307 scopus 로고    scopus 로고
    • GALILEO Study Group. Intravitreal aflibercept for macular edema secondary to central retinal vein occlusion: 18-month results of the phase 3 GALILEO study
    • Ogura Y, Roider J, Korobelnik JF, et al; GALILEO Study Group. Intravitreal aflibercept for macular edema secondary to central retinal vein occlusion: 18-month results of the phase 3 GALILEO study. Am J Ophthalmol. 2014;158(5):1032–1038.
    • (2014) Am J Ophthalmol , vol.158 , Issue.5 , pp. 1032-1038
    • Ogura, Y.1    Roider, J.2    Korobelnik, J.F.3
  • 10
    • 84903819352 scopus 로고    scopus 로고
    • Intravitreal aflibercept injection for macular edema due to central retinal vein occlusion: Two-year results from the COPERNICUS study
    • Heier JS, Clark WL, Boyer DS, et al. Intravitreal aflibercept injection for macular edema due to central retinal vein occlusion: two-year results from the COPERNICUS study. Ophthalmology. 2014;121(7):1414–1420.
    • (2014) Ophthalmology , vol.121 , Issue.7 , pp. 1414-1420
    • Heier, J.S.1    Clark, W.L.2    Boyer, D.S.3
  • 11
    • 80052857441 scopus 로고    scopus 로고
    • Ozurdex GENEVA Study Group. Dexamethasone intravitreal implant in patients with macular edema related to branch or central retinal vein occlusion twelve-month study results
    • Haller JA, Bandello F, Belfort R Jr, et al; Ozurdex GENEVA Study Group. Dexamethasone intravitreal implant in patients with macular edema related to branch or central retinal vein occlusion twelve-month study results. Ophthalmology. 2011;118(12):2453–2460.
    • (2011) Ophthalmology , vol.118 , Issue.12 , pp. 2453-2460
    • Haller, J.A.1    Bandello, F.2    Belfort, R.3
  • 12
    • 84904395653 scopus 로고    scopus 로고
    • Dexamethasone intravitreal implant for the treatment of macular oedema secondary to retinal vein occlusion. NICE technology appraisal guidance. TA229, July 2011
    • National Institute for Health and Care Excellence. Dexamethasone intravitreal implant for the treatment of macular oedema secondary to retinal vein occlusion. NICE technology appraisal guidance. TA229, July 2011. Available from: https://www.nice.org.uk/guidance/ta229. Accessed July 17, 2015.
    • National Institute for Health and Care Excellence
  • 13
    • 84904395653 scopus 로고    scopus 로고
    • Ranibizumab for treating visual impairment caused by macular oedema secondary to retinal vein occlusion. NICE technology appraisal guidance. TA283, May 2013
    • National Institute for Health and Care Excellence. Ranibizumab for treating visual impairment caused by macular oedema secondary to retinal vein occlusion. NICE technology appraisal guidance. TA283, May 2013. Available from: https://www.nice.org.uk/guidance/ta283. Accessed July 17, 2015.
    • National Institute for Health and Care Excellence
  • 14
    • 84904395653 scopus 로고    scopus 로고
    • Aflibercept for treat­ing visual impairment caused by macular oedema secondary to central retinal vein occlusion. NICE technology appraisal guidance. TA305, February 2014
    • National Institute for Health and Care Excellence. Aflibercept for treat­ing visual impairment caused by macular oedema secondary to central retinal vein occlusion. NICE technology appraisal guidance. TA305, February 2014. Available from: https://www.nice.org.uk/guidance/ta305. Accessed July 17, 2015.
    • National Institute for Health and Care Excellence
  • 15
    • 36448993366 scopus 로고    scopus 로고
    • Pan American Collaborative Retina Group (PACORES). Twelve-month safety of intravitreal injections of bevacizumab (Avastin): Results of the Pan-American Collaborative Retina Study Group (PACORES)
    • Wu L, Martínez-Castellanos MA, Quiroz-Mercado H, et al; Pan American Collaborative Retina Group (PACORES). Twelve-month safety of intravitreal injections of bevacizumab (Avastin): results of the Pan-American Collaborative Retina Study Group (PACORES). Graefes Arch Clin Exp Ophthalmol. 2008;246(1):81–87.
    • (2008) Graefes Arch Clin Exp Ophthalmol , vol.246 , Issue.1 , pp. 81-87
    • Wu, L.1    Martínez-Castellanos, M.A.2    Quiroz-Mercado, H.3
  • 16
    • 34247231034 scopus 로고    scopus 로고
    • Intra­vitreal bevacizumab (Avastin) in the treatment of macular edema sec­ondary to branch retinal vein occlusion
    • Rabena MD, Pieramici DJ, Castellarin AA, Nasir MA, Avery RL. Intra­vitreal bevacizumab (Avastin) in the treatment of macular edema sec­ondary to branch retinal vein occlusion. Retina. 2007;27(4):419–425.
    • (2007) Retina , vol.27 , Issue.4 , pp. 419-425
    • Rabena, M.D.1    Pieramici, D.J.2    Castellarin, A.A.3    Nasir, M.A.4    Avery, R.L.5
  • 17
    • 84870708962 scopus 로고    scopus 로고
    • Benefit from bevacizumab for macular edema in central retinal vein occlusion: Twelve-month results of a prospective, randomized study
    • Epstein DL, Algvere PV, von Wendt G, Seregard S, Kvanta A. Benefit from bevacizumab for macular edema in central retinal vein occlusion: twelve-month results of a prospective, randomized study. Ophthalmology. 2012;119(12):2587–2591.
    • (2012) Ophthalmology , vol.119 , Issue.12 , pp. 2587-2591
    • Epstein, D.L.1    Algvere, P.V.2    Von Wendt, G.3    Seregard, S.4    Kvanta, A.5
  • 18
    • 84892595664 scopus 로고    scopus 로고
    • Two-year outcomes of intravitreal bevacizumab therapy for macular oedema secondary to branch retinal vein occlusion
    • Hikichi T, Higuchi M, Matsushita T, et al. Two-year outcomes of intravitreal bevacizumab therapy for macular oedema secondary to branch retinal vein occlusion. Br J Ophthalmol. 2014;98(2):195–199.
    • (2014) Br J Ophthalmol , vol.98 , Issue.2 , pp. 195-199
    • Hikichi, T.1    Higuchi, M.2    Matsushita, T.3
  • 19
    • 77954759614 scopus 로고    scopus 로고
    • Novel method for analyzing Snel­len visual acuity measurements
    • Gregori NZ, Feuer W, Rosenfeld PJ. Novel method for analyzing Snel­len visual acuity measurements. Retina. 2010;30(7):1046–1050.
    • (2010) Retina , vol.30 , Issue.7 , pp. 1046-1050
    • Gregori, N.Z.1    Feuer, W.2    Rosenfeld, P.J.3
  • 21
    • 84937738744 scopus 로고    scopus 로고
    • A randomised, double-masked, controlled study of the efficacy and safety of intravitreal bevacizumab versus ranibizumab in the treatment of macular oedema due to branch retinal vein occlusion: MARVEL Report No. 1
    • Narayanan R, Panchal B, Das T, Chhablani J, Jalali S, Ali MH; MARVEL Study Group. A randomised, double-masked, controlled study of the efficacy and safety of intravitreal bevacizumab versus ranibizumab in the treatment of macular oedema due to branch retinal vein occlusion: MARVEL Report No. 1. Br J Ophthalmol. January 28, 2015.
    • (2015) Br J Ophthalmol , pp. 28
    • Narayanan, R.1    Panchal, B.2    Das, T.3    Chhablani, J.4    Jalali, S.5    Ali, M.H.6
  • 22
    • 84905090578 scopus 로고    scopus 로고
    • Intravitreal ranibizumab for retinal vein occlusion through 1 year in clinical practice
    • Brynskov T, Kemp H, Sørensen TL. Intravitreal ranibizumab for retinal vein occlusion through 1 year in clinical practice. Retina. 2014;34(8):1637–1643.
    • (2014) Retina , vol.34 , Issue.8 , pp. 1637-1643
    • Brynskov, T.1    Kemp, H.2    Sørensen, T.L.3
  • 23
    • 84893473269 scopus 로고    scopus 로고
    • Testing the effectiveness of intravitreal ranibizumab during 12 months of follow-up in venous occlusion treatment
    • Pacella E, Pacella F, La Torre G, et al. Testing the effectiveness of intravitreal ranibizumab during 12 months of follow-up in venous occlusion treatment. Clin Ther. 2012;163(6):e413–e422.
    • (2012) Clin Ther , vol.163 , Issue.6
    • Pacella, E.1    Pacella, F.2    La Torre, G.3
  • 24
    • 84886430519 scopus 로고    scopus 로고
    • IVAN Study Investiga­tors. Alternative treatments to inhibit VEGF in age-related choroidal neovascularization: 2-year findings of the IVAN randomized controlled trial
    • Chakravarthy U, Harding SP, Rogers CA, et al; IVAN Study Investiga­tors. Alternative treatments to inhibit VEGF in age-related choroidal neovascularization: 2-year findings of the IVAN randomized controlled trial. Lancet. 2013;382(9900):1258–1267.
    • (2013) Lancet , vol.382 , Issue.9900 , pp. 1258-1267
    • Chakravarthy, U.1    Harding, S.P.2    Rogers, C.A.3
  • 25
    • 84863320414 scopus 로고    scopus 로고
    • Ranibizumab and bevacizumab for treatment of neovascular age-related macular degeneration: Two-year results
    • Comparison of Age-related Macular Degeneration Treatments Trials (CATT) Research Group, Martin DF, Maguire MG, Fine SL, et al. Ranibizumab and bevacizumab for treatment of neovascular age-related macular degeneration: two-year results. Ophthalmology. 2012;119(7):1388–1398.
    • (2012) Ophthalmology , vol.119 , Issue.7 , pp. 1388-1398
    • Martin, D.F.1    Maguire, M.G.2    Fine, S.L.3
  • 26
    • 84888643134 scopus 로고    scopus 로고
    • Intravitreal anti-VEGF therapy for choroidal neovascularization secondary to pathological myopia: 4-year outcome (with CATT and IVAN)
    • Ruiz-Moreno JM, Arias L, Montero JA, Carneiro A, Silva R. Intravitreal anti-VEGF therapy for choroidal neovascularization secondary to pathological myopia: 4-year outcome (with CATT and IVAN). Br J Ophthalmol. 2013;97(11):1447–1450.
    • (2013) Br J Ophthalmol , vol.97 , Issue.11 , pp. 1447-1450
    • Ruiz-Moreno, J.M.1    Arias, L.2    Montero, J.A.3    Carneiro, A.4    Silva, R.5
  • 27
    • 84882254907 scopus 로고    scopus 로고
    • A prospective randomized trial of intravitreal bevacizumab versus ranibizumab for the management of diabetic macular edema
    • Nepomuceno AB, Takaki E, Paes de Almeida FP, et al. A prospective randomized trial of intravitreal bevacizumab versus ranibizumab for the management of diabetic macular edema. Am J Ophthalmol. 2013;156(3):502–510.e2.
    • (2013) Am J Ophthalmol , vol.156 , Issue.3
    • Nepomuceno, A.B.1    Takaki, E.2    De Paes Almeida, F.P.3
  • 28
    • 84866598095 scopus 로고    scopus 로고
    • The relative clinical effectiveness of ranibizumab and bevacizumab in diabetic macular oedema: An indirect comparison in a systematic review (with IVAN and CATT)
    • Ford JA, Elders A, Shyangdan D, Royle P, Waugh N. The relative clinical effectiveness of ranibizumab and bevacizumab in diabetic macular oedema: an indirect comparison in a systematic review (with IVAN and CATT). BMJ. 2012;345:e5182.
    • (2012) BMJ , vol.345
    • Ford, J.A.1    Elders, A.2    Shyangdan, D.3    Royle, P.4    Waugh, N.5
  • 29
    • 84925423332 scopus 로고    scopus 로고
    • Comparative effectiveness randomized clinical trial of aflibercept, bevacizumab, or ranibizumab for diabetic macular edema, protocol T
    • Retinopathy Clinical Research Network
    • Retinopathy Clinical Research Network, Wells JA, Glassman AR, Ayala AR, et al. Comparative effectiveness randomized clinical trial of aflibercept, bevacizumab, or ranibizumab for diabetic macular edema, protocol T. N Engl J Med. 2015;372:1193–1203.
    • (2015) N Engl J Med , vol.372 , pp. 1193-1203
    • Wells, J.A.1    Glassman, A.R.2    Ayala, A.R.3
  • 30
    • 84920748073 scopus 로고    scopus 로고
    • Comparison of ranibi­zumab and bevacizumab for neovascular age-related macular degenera­tion according to LUCAS treat-and-extend protocol
    • Berg K, Pedersen TR, Sandvik L, Bragadóttir R. Comparison of ranibi­zumab and bevacizumab for neovascular age-related macular degenera­tion according to LUCAS treat-and-extend protocol. Ophthalmology. 2015;122(1):146–152.
    • (2015) Ophthalmology , vol.122 , Issue.1 , pp. 146-152
    • Berg, K.1    Pedersen, T.R.2    Sandvik, L.3    Bragadóttir, R.4
  • 31
    • 84940390831 scopus 로고    scopus 로고
    • Neovascular events in eyes with central retinal vein occlusion undergoing serial bevacizumab or ranibizumab intravitreal injections: A retrospective review
    • DeCroos FC, Todorich B, Alshareef R, et al. Neovascular events in eyes with central retinal vein occlusion undergoing serial bevacizumab or ranibizumab intravitreal injections: a retrospective review. J Ophthalmic Vis Res. 2014;9(4):461–468.
    • (2014) J Ophthalmic Vis Res , vol.9 , Issue.4 , pp. 461-468
    • Decroos, F.C.1    Todorich, B.2    Alshareef, R.3


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.